美股A股
StockGist
Back
6-K2026-04-16· grok-4-1-fast-non-reasoning

UPC · Universe Pharmaceuticals Inc.

0001213900-26-044641

SEC filing

Summary

Universe Pharmaceuticals INC filed Exhibit 10.1 disclosing adoption of the 2026 Equity Incentive Plan to attract, retain personnel, and align interests with shareholders through equity awards.

Key takeaways

Full analysis

The 2026 Equity Incentive Plan enables Universe Pharmaceuticals INC, a Cayman Islands exempted company, to grant various equity-based awards to service providers including employees, directors, and consultants. This standard compensation mechanism aims to retain talent and align incentives with shareholder interests by tying compensation to company performance. Key features include performance-based awards qualifying under Section 162(m) of the U.S. Internal Revenue Code, with goals measurable against financial metrics such as operating income, earnings per share, total shareholder return, and share price over periods up to 36 months. The plan defines triggering events like Change in Control, which includes acquisition of 50%+ voting power, asset sales, board changes, or certain mergers, potentially accelerating vesting. Fair Market Value uses Nasdaq closing prices or board-determined values, ensuring compliance with Applicable Laws including Cayman Islands regulations and U.S. securities rules. No share reserve or specific grant details are disclosed in the exhibit.